Vanta Bioscience Ltd - 540729 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Zoheb SayaniDesignation :- Company Secretary and Compliance Officer Vanta Bioscience Ltd - 540729 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayVanta Bioscience Ltd 2CINU74999TG2016PLC109280 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 13.24 4Highest Credit Rating during the previous FY INDBB- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: ZohebSayani Designation: CompanySecretary EmailId: cs@vantabio.com Name of the Chief Financial Officer: Kiran Kumar Annabatula Designation: CFO EmailId: ceo@vantabio.com Date: 25/05/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Vanta Bioscience Ltd - 540729 - Financial Results For The Half Year And Year Ended 31.03.2019
Outcome of Board Meeting dated May 22, 2019 along with standalone and consolidated financial statements for the half year and year ended 31.03.2019 Vanta Bioscience Ltd - 540729 - Board Meeting Intimation for Approval Of Standalone And Consolidated Audited Financial Statements Of The Company For The Half Year And Year Ended March 31, 2019 And Other Matters
Vanta Bioscience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2019 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Statements of the Company for the half year and year ended March 31, 2019 and other matters. Vanta Bioscience Ltd - 540729 - Shareholding for the Period Ended March 31, 2019
Vanta Bioscience Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here Vanta Bioscience Ltd - 540729 - Compliance Certificate Under Regulation 40 (9) Of SEBI (LODR) Regulations, 2015 For The Half Year Ended March 31, 2019
Compliance Certificate under Regulation 40 (9) of SEBI (LODR) Regulations, 2015 for the half year ended March 31, 2019 Vanta Bioscience Ltd - 540729 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Vanta Bioscience Limited through its subsidiary - Vayam Research Solutions Limited signs CRO Service Agreement of Rs. 29 Crores with Emcure Pharmaceuticals Limited Vanta Bioscience Ltd - 540729 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Zoheb SayaniDesignation :- Company Secretary and Compliance Officer 